Company intelligence / Profile preview

ImmuLogic Pharmaceutical Corporation

Cambridge, Massachusetts, United Statessbir.gov ↗

Ownership: Private
Employees: ~72
Development stage: Phase 2

Overview

ImmuLogic was a development-stage biotech company in the late 1980s and early 1990s focused on novel biotechnological approaches to treat allergies. As of its IPO consideration in 1991, it had not yet entered Phase 1 human trials and remained pre-revenue except for research contracts with Merck. Its lead product targeted cat allergies and was expected to be ready by the mid-1990s. The company raised significant venture capital and formed strategic alliances but ultimately did not reach commercialization before ceasing operations.

Therapeutic areas: Immunology
Modalities: Biotechnology-derived therapeutics (primarily focused on allergy treatments, likely protein-based or peptide-based therapies)
Industry: Biotech

Drug pipeline

1 asset

Allervax Cat

Unknown

Partnerships

Merck & Co. (research contract and equity investment)

Beyond the preview

Go deeper on ImmuLogic Pharmaceutical Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImmuLogic Pharmaceutical Corporation.

Explore the full profile